GlassScriptPhysician profile
Kasee A Wiesen
NPI 1487214664
$2,634.36
in general payments reported to CMS, 2019-2025
35 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $402 · 2022: $727 · 2023: $864 · 2024: $445 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.77 | 2021-2025 | |
| Amgen INC. | $339.80 | 2021-2025 | Evenity, Prolia, Otezla |
| Otsuka America Pharmaceutical, INC. | $326.09 | 2022-2025 | Rexulti |
| Pfizer INC. | $134.90 | 2023-2024 | |
| Novo Nordisk INC | $134.28 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.20 | 2021-2023 | Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $105.14 | 2021-2025 | Xigduo, Airsupra |
| Janssen Pharmaceuticals, INC | $101.20 | 2021-2023 | Xarelto |
| Lilly USA, LLC | $58.03 | 2021-2025 | Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $53.50 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.52 | 2021-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $49.78 | 2021-2023 | |
| Welch Allyn | $45.23 | 2021 | |
| Genentech USA, INC. | $32.05 | 2021-2022 | |
| Ardelyx, INC. | $30.83 | 2024-2025 | Ibsrela |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.40 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $28.59 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $27.07 | 2021-2022 | |
| Lundbeck LLC | $20.01 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $19.46 | 2022 | |
| Amarin Pharma, INC. | $18.42 | 2021 | |
| Almatica Pharma LLC | $17.28 | 2023 | Loreev Xr |
| Gilead Sciences, INC. | $17.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.95 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.93 | 2022 | |
| Dexcom, INC. | $15.88 | 2021 | |
| Esperion Therapeutics, INC. | $14.46 | 2023 | Nexletol |
| Insulet Corporation | $14.13 | 2023 | Omnipod |
| Glaxosmithkline, LLC. | $14.06 | 2023 | Shingrix, Arexvy |
| Avanir Pharmaceuticals, INC. | $13.46 | 2022 | |
| Zealand Pharma US, INC. | $13.43 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.40 | 2024 | Hetlioz, Fanapt |
| Astellas Pharma US INC | $13.35 | 2021 | |
| Axsome Therapeutics, INC. | $12.86 | 2023 | Auvelity |
| Philips North America LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasee Wiesen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.